{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T07:41:34Z","timestamp":1794555694511,"version":"4.9.1"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":2283,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,6]]},"DOI":"10.1111\/j.1365-2133.2009.09037.x","type":"journal-article","created":{"date-parts":[[2009,2,16]],"date-time":"2009-02-16T07:32:00Z","timestamp":1234769520000},"page":"1299-1307","source":"Crossref","is-referenced-by-count":101,"title":["Bexarotene therapy for mycosis fungoides and S\u00e9zary syndrome"],"prefix":"10.1093","volume":"160","author":[{"given":"R.A.","family":"Abbott","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.J.","family":"Whittaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.L.","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Russell-Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.J.","family":"Bashir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.J.","family":"Scarisbrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","reference":[{"key":"10.1111\/j.1365-2133.2009.09037.x-BIB1","volume-title":"Rook\u2019s Textbook of Dermatology","author":"Whittaker","year":"2004"},{"key":"10.1111\/j.1365-2133.2009.09037.x-BIB2","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1001\/archderm.143.7.854","article-title":"Incidence of cutaneous T-cell lymphoma in the United States, 1973-2002","volume":"143","author":"Criscione","year":"2007","journal-title":"Arch Dermatol"},{"key":"10.1111\/j.1365-2133.2009.09037.x-BIB3","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1001\/archderm.139.7.857","article-title":"Long-term outcome of 525 patients with mycosis fungoides and S\u00e9zary syndrome","volume":"139","author":"Kim","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1111\/j.1365-2133.2009.09037.x-BIB4","doi-asserted-by":"crossref","first-page":"3768","DOI":"10.1182\/blood-2004-09-3502","article-title":"WHO-EORTC classification for cutaneous lymphomas","volume":"105","author":"Willemze","year":"2005","journal-title":"Blood"},{"key":"10.1111\/j.1365-2133.2009.09037.x-BIB5","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.ejca.2006.01.025","article-title":"EORTC consensus recommendations for the treatment of mycosis fungoides\/S\u00e9zary syndrome","volume":"42","author":"Trautinger","year":"2006","journal-title":"Eur J Cancer"},{"key":"10.1111\/j.1365-2133.2009.09037.x-BIB6","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1159\/000018214","article-title":"Cutaneous T cell lymphoma: update of treatment","volume":"199","author":"Zackheim","year":"1999","journal-title":"Dermatology"},{"key":"10.1111\/j.1365-2133.2009.09037.x-BIB7","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1021\/jm00044a014","article-title":"Synthesis and structure-activity relationships of novel retinoid X receptor-selective retinoids","volume":"37","author":"Boehm","year":"1994","journal-title":"J Med Chem"},{"key":"10.1111\/j.1365-2133.2009.09037.x-BIB8","first-page":"581","article-title":"Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma","volume":"137","author":"Duvic","year":"2001","journal-title":"Arch Dermatol"},{"key":"10.1111\/j.1365-2133.2009.09037.x-BIB9","first-page":"1234","article-title":"Induction of apoptosis by bexarotene in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action","volume":"8","author":"Zhang","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.1111\/j.1365-2133.2009.09037.x-BIB10","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1001\/archderm.141.3.315","article-title":"Biological effects of bexarotene in cutaneous T-cell lymphoma","volume":"141","author":"Budgin","year":"2005","journal-title":"Arch Dermatol"},{"key":"10.1111\/j.1365-2133.2009.09037.x-BIB11","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1067\/mjd.2002.124607","article-title":"Optimizing bexarotene therapy for cutaneous T-cell lymphoma","volume":"47","author":"Talpur","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1365-2133.2009.09037.x-BIB12","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.jaad.2003.05.010","article-title":"Cutaneous T-cell lymphoma treatment using bexarotene and PUVA: a case series","volume":"51","author":"Singh","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1365-2133.2009.09037.x-BIB13","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/j.1365-2133.2006.07329.x","article-title":"Minimizing adverse side-effects of oral bexarotene in cutaneous T-cell lymphoma: an expert opinion","volume":"155","author":"Assaf","year":"2006","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1365-2133.2009.09037.x-BIB14","first-page":"725","article-title":"Report of the Committee of staging and classification of cutaneous T-cell lymphomas","volume":"63","author":"Bunn","year":"1979","journal-title":"Cancer Treat Rep"},{"key":"10.1111\/j.1365-2133.2009.09037.x-BIB15","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1182\/blood-2007-03-055749","article-title":"Revisions to the staging and classification of mycosis fungoides and S\u00e9zary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC)","volume":"110","author":"Olsen","year":"2007","journal-title":"Blood"},{"key":"10.1111\/j.1365-2133.2009.09037.x-BIB16","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1200\/JCO.2001.19.9.2456","article-title":"Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase I-II trial results","volume":"19","author":"Duvic","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1365-2133.2009.09037.x-BIB17","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jaad.2003.11.058","article-title":"Comparison of selective retinoic acid receptor- and retinoic X receptor-mediated efficacy, tolerance and survival in cutaneous T-cell lymphoma","volume":"51","author":"Querfield","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1365-2133.2009.09037.x-BIB18","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1002\/ajh.20952","article-title":"Bexarotene blunts malignant T-cell chemotaxis in S\u00e9zary syndrome: reduction of chemokine receptor 4-positive lymphocytes and decreased chemotaxis to thymus and activation-regulated chemokine","volume":"82","author":"Richardson","year":"2007","journal-title":"Am J Hematol"},{"key":"10.1111\/j.1365-2133.2009.09037.x-BIB19","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/j.1365-2133.2007.07975.x","article-title":"The optimal use of bexarotene in cutaneous T-cell lymphoma","volume":"157","author":"Gniadecki","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1365-2133.2009.09037.x-BIB20","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.jaad.2005.02.055","article-title":"Bexarotene treatment of late-stage mycosis fungoides and S\u00e9zary syndrome: development of extracutaneous lymphoma in 6 patients","volume":"52","author":"Bouwhis","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1365-2133.2009.09037.x-BIB21","first-page":"241","article-title":"Low dose bexarotene capsules and phototherapy for early stage cutaneous T-cell lymphoma","volume":"119","author":"Guitart","year":"2002","journal-title":"J Invest Dermatol"},{"key":"10.1111\/j.1365-2133.2009.09037.x-BIB22","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1001\/archderm.144.6.738","article-title":"Folliculotropic mycosis fungoides: an aggressive variant of cutaneous T cell lymphoma","volume":"144","author":"Gerami","year":"2008","journal-title":"Arch Dermatol"},{"key":"10.1111\/j.1365-2133.2009.09037.x-BIB23","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/j.1600-0781.2007.00315.x","article-title":"Bexarotene and narrowband ultraviolet B phototherapy combination treatment for mycosis fungoides","volume":"23","author":"Lokitz","year":"2007","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"10.1111\/j.1365-2133.2009.09037.x-BIB24","first-page":"536","article-title":"Oral bexarotene therapy combined with phototherapy in the management of cutaneous T-cell lymphoma","volume":"117","author":"Heald","year":"2001","journal-title":"J Invest Dermatol"},{"key":"10.1111\/j.1365-2133.2009.09037.x-BIB25","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1111\/j.1365-2133.2007.07901.x","article-title":"Extracorporeal photopheresis in combination with bexarotene in the treatment of mycosis fungoides and S\u00e9zary syndrome","volume":"156","author":"Tsirigotis","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1365-2133.2009.09037.x-BIB26","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1001\/archderm.141.3.301","article-title":"Low-dose bexarotene and low-dose interferon alfa-2b for adult T-cell leukaemia\/lymphoma associated with human T-lymphotropic virus 1","volume":"141","author":"Richardson","year":"2005","journal-title":"Arch Dermatol"},{"key":"10.1111\/j.1365-2133.2009.09037.x-BIB27","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1067\/mjd.2001.117519","article-title":"Regression of multifocal, skin-restricted, CD30-positive large T-cell lymphoma with interferon alfa and bexarotene therapy","volume":"45","author":"French","year":"2001","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1365-2133.2009.09037.x-BIB28","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1182\/blood.V104.11.2644.2644","article-title":"Results of a phase II trial of oral bexarotene combined with interferon alfa-2b for patients with cutaneous T-cell lymphoma","volume":"104","author":"Straus","year":"2004","journal-title":"Blood"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2133.2009.09037.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1365-2133.2009.09037.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T08:44:16Z","timestamp":1676364256000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/160\/6\/1299\/6641959"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,6]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2009,6]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1365-2133.2009.09037.x","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,6]]}}}